MedTrace Logo

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104

NCT01448395 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-09-01

No results posted yet for this study

Summary

A study to look at how radiolabelled NXL104 is taken up, broken down and removed by the body when given as an injection into the blood stream.

Conditions

  • Healthy

Interventions

DRUG

[14C]NXL104

500mg/100mL intravenous solution

Sponsors & Collaborators

Principal Investigators

  • Paul Newell, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448395 on ClinicalTrials.gov